<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4E777F7E-8B7E-406A-87FB-39A7026F891F"><gtr:id>4E777F7E-8B7E-406A-87FB-39A7026F891F</gtr:id><gtr:name>Uppsala University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4E682F0C-74B5-4907-891D-7BAC440B9540"><gtr:id>4E682F0C-74B5-4907-891D-7BAC440B9540</gtr:id><gtr:name>University of Georgia</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E30B7145-0051-47F4-B2D6-C93EE14B8568"><gtr:id>E30B7145-0051-47F4-B2D6-C93EE14B8568</gtr:id><gtr:name>University of Oslo</gtr:name><gtr:address><gtr:line1>Boks 1072 Blindern</gtr:line1><gtr:line4>Oslo</gtr:line4><gtr:line5>NO 0316</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Norway</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D2D9079A-7C22-416E-84A8-4F37FF19A482"><gtr:id>D2D9079A-7C22-416E-84A8-4F37FF19A482</gtr:id><gtr:name>Callaghan Innovation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0CF23EC6-EA76-4813-BB6B-803FF1050B4A"><gtr:id>0CF23EC6-EA76-4813-BB6B-803FF1050B4A</gtr:id><gtr:name>Industrial Research Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/308C1B48-278F-44D4-A65F-12A0D8DE1068"><gtr:id>308C1B48-278F-44D4-A65F-12A0D8DE1068</gtr:id><gtr:name>Victoria University of Wellington</gtr:name><gtr:address><gtr:line1>PO Box 600</gtr:line1><gtr:line4>Wellington</gtr:line4><gtr:postCode>6140</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>New Zealand</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:department>Sch of Biological Sciences</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4E777F7E-8B7E-406A-87FB-39A7026F891F"><gtr:id>4E777F7E-8B7E-406A-87FB-39A7026F891F</gtr:id><gtr:name>Uppsala University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4E682F0C-74B5-4907-891D-7BAC440B9540"><gtr:id>4E682F0C-74B5-4907-891D-7BAC440B9540</gtr:id><gtr:name>University of Georgia</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E30B7145-0051-47F4-B2D6-C93EE14B8568"><gtr:id>E30B7145-0051-47F4-B2D6-C93EE14B8568</gtr:id><gtr:name>University of Oslo</gtr:name><gtr:address><gtr:line1>Boks 1072 Blindern</gtr:line1><gtr:line4>Oslo</gtr:line4><gtr:line5>NO 0316</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Norway</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D2D9079A-7C22-416E-84A8-4F37FF19A482"><gtr:id>D2D9079A-7C22-416E-84A8-4F37FF19A482</gtr:id><gtr:name>Callaghan Innovation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0CF23EC6-EA76-4813-BB6B-803FF1050B4A"><gtr:id>0CF23EC6-EA76-4813-BB6B-803FF1050B4A</gtr:id><gtr:name>Industrial Research Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/308C1B48-278F-44D4-A65F-12A0D8DE1068"><gtr:id>308C1B48-278F-44D4-A65F-12A0D8DE1068</gtr:id><gtr:name>Victoria University of Wellington</gtr:name><gtr:address><gtr:line1>PO Box 600</gtr:line1><gtr:line4>Wellington</gtr:line4><gtr:postCode>6140</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>New Zealand</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8D381AAA-E001-4B4F-8C29-3C468F3AFC6C"><gtr:id>8D381AAA-E001-4B4F-8C29-3C468F3AFC6C</gtr:id><gtr:firstName>Jerry</gtr:firstName><gtr:surname>Turnbull</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FD525713%2F1"><gtr:id>55F9793B-37C5-4368-BEF7-B2D6AA139A21</gtr:id><gtr:title>Evaluation of optimised heparins as novel therapeutics for Alzheimers Disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/D525713/1</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The key step in the generation of toxic Abeta peptides that cause Alzheimer's disease (AD) is the action of an enzyme known as BACE1. We have recently discovered that a naturally occurring complex sugar called heparan sulphate (HS) is a regulator of BACE1 activity. The anti-coagulant drug heparin is a member of the HS family of molecules and we have generated a semi-synthetic modified heparin as a lead compound which is a powerful BACE1 inhibitor, has very low anticoagulant activity, and is not toxic in mice. Optimised heparins thus have potential as a new class of anti-AD drugs. In this proposal we will test a novel modified heparin in a validated mouse model of AD, and make initial assessments of the bioavailability of the compound and its ability to cross the blood/brain barrier. An assessment of the potential market for a novel heparin-based Alzheimer's drug will also be made. The overall goal of this project will be to establish proof-of-concept in an animal model of the use of an optimised heparin as a novel treatment for Alzheimer's Disease. This will enhance the opportunities for commercial exploitation through either a licening deal or development of a spin out company.</gtr:technicalSummary><gtr:fund><gtr:end>2007-08-07</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2006-05-08</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>59839</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Victoria University of Wellington</gtr:collaboratingOrganisation><gtr:country>New Zealand</gtr:country><gtr:department>Ferrier Research Institute</gtr:department><gtr:description>Synthetic chemistry for HS analogues</gtr:description><gtr:id>0D35C0E8-A429-45D6-9D37-54CDBBFDBE66</gtr:id><gtr:impact>Publication in JACS and Chem Euro Journal and ongoing collaborations</gtr:impact><gtr:outcomeId>92765CB861E-4</gtr:outcomeId><gtr:partnerContribution>Development of advanced synthetic chemistry to produce heparan sulphate saccharides Major contribution in kind through New Zealand government grants to fund their chemistry development</gtr:partnerContribution><gtr:piContribution>Design of target molecules for synthesis and provision of bioassays for screening</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oslo</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:department>Department of Medical Biochemistry</gtr:department><gtr:description>Animal testing of AD secretase inhibitors</gtr:description><gtr:id>B0C6739F-7A8B-46DB-BF46-C2F1A133E9C6</gtr:id><gtr:impact>IP and patenting + publications</gtr:impact><gtr:outcomeId>C7B20B0AF70-3</gtr:outcomeId><gtr:partnerContribution>Provision of transgenic mouse models of AD</gtr:partnerContribution><gtr:piContribution>Develeopment of novel compounds as inhibitors for the Alzheimers beta-secretase</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Callaghan Innovation</gtr:collaboratingOrganisation><gtr:country>New Zealand</gtr:country><gtr:department>Carbohydrate Chemistry</gtr:department><gtr:description>Synthetic chemistry for HS analogues</gtr:description><gtr:id>31339185-AD12-4D08-A14D-AB2B4A465A4E</gtr:id><gtr:impact>Publication in JACS and Chem Euro Journal and ongoing collaborations</gtr:impact><gtr:outcomeId>92765CB861E-3</gtr:outcomeId><gtr:partnerContribution>Development of advanced synthetic chemistry to produce heparan sulphate saccharides Major contribution in kind through New Zealand government grants to fund their chemistry development</gtr:partnerContribution><gtr:piContribution>Design of target molecules for synthesis and provision of bioassays for screening</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Georgia</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Synthetic chemistry for HS analogues</gtr:description><gtr:id>7FCD242A-5662-48DB-BF2A-FA01DCC1B50A</gtr:id><gtr:impact>Publication in JACS and Chem Euro Journal and ongoing collaborations</gtr:impact><gtr:outcomeId>92765CB861E-1</gtr:outcomeId><gtr:partnerContribution>Development of advanced synthetic chemistry to produce heparan sulphate saccharides Major contribution in kind through New Zealand government grants to fund their chemistry development</gtr:partnerContribution><gtr:piContribution>Design of target molecules for synthesis and provision of bioassays for screening</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Uppsala University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>Department of Medical Biochemistry and Microbiology</gtr:department><gtr:description>Animal testing of AD secretase inhibitors</gtr:description><gtr:id>B3011EAB-1CB3-4488-A780-FE198077E3A4</gtr:id><gtr:impact>IP and patenting + publications</gtr:impact><gtr:outcomeId>C7B20B0AF70-2</gtr:outcomeId><gtr:partnerContribution>Provision of transgenic mouse models of AD</gtr:partnerContribution><gtr:piContribution>Develeopment of novel compounds as inhibitors for the Alzheimers beta-secretase</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Industrial Research Ltd</gtr:collaboratingOrganisation><gtr:country>New Zealand</gtr:country><gtr:department>Glycochemistry Division</gtr:department><gtr:description>Synthetic chemistry for HS analogues</gtr:description><gtr:id>3C9948A6-11CC-4D71-9B73-1FBC308D75C4</gtr:id><gtr:impact>Publication in JACS and Chem Euro Journal and ongoing collaborations</gtr:impact><gtr:outcomeId>92765CB861E-2</gtr:outcomeId><gtr:partnerContribution>Development of advanced synthetic chemistry to produce heparan sulphate saccharides Major contribution in kind through New Zealand government grants to fund their chemistry development</gtr:partnerContribution><gtr:piContribution>Design of target molecules for synthesis and provision of bioassays for screening</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Callaghan Innovation</gtr:collaboratingOrganisation><gtr:country>New Zealand</gtr:country><gtr:description>Synthetic chemistry for heparan sulfate analogues</gtr:description><gtr:id>23765203-0F15-4D05-B304-4E5DB0BFBAB2</gtr:id><gtr:outcomeId>b96291cab96291e8-1</gtr:outcomeId><gtr:piContribution>International collaboration to develop synthetic chemistry for heparin/HS glycans</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leicester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Genetics</gtr:department><gtr:description>Animal testing of AD secretase inhibitors</gtr:description><gtr:id>741F730B-6DC1-4CFC-9311-454B7237D4C0</gtr:id><gtr:impact>IP and patenting + publications</gtr:impact><gtr:outcomeId>C7B20B0AF70-1</gtr:outcomeId><gtr:partnerContribution>Provision of transgenic mouse models of AD</gtr:partnerContribution><gtr:piContribution>Develeopment of novel compounds as inhibitors for the Alzheimers beta-secretase</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Callaghan Innovation</gtr:collaboratingOrganisation><gtr:country>New Zealand</gtr:country><gtr:department>Carbohydrate Chemistry</gtr:department><gtr:description>Development of AD therapeutics</gtr:description><gtr:id>A7479A1C-47EF-48AE-9B93-9E34E3067CF4</gtr:id><gtr:impact>Chem Eur J publication, further manuscripts in preparation, joint funding and IP patent submissions</gtr:impact><gtr:outcomeId>538307427a76f7.91630409-1</gtr:outcomeId><gtr:partnerContribution>Developing synthetic chemistry for BACE inhibitors and providing compounds and radiolabelled compounds</gtr:partnerContribution><gtr:piContribution>Providing target structures and bioassays</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Victoria University of Wellington</gtr:collaboratingOrganisation><gtr:country>New Zealand</gtr:country><gtr:department>Ferrier Research Institute</gtr:department><gtr:description>Development of AD therapeutics</gtr:description><gtr:id>D438301F-2CF1-46E7-8F39-F739B5959F4C</gtr:id><gtr:impact>Chem Eur J publication, further manuscripts in preparation, joint funding and IP patent submissions</gtr:impact><gtr:outcomeId>538307427a76f7.91630409-2</gtr:outcomeId><gtr:partnerContribution>Developing synthetic chemistry for BACE inhibitors and providing compounds and radiolabelled compounds</gtr:partnerContribution><gtr:piContribution>Providing target structures and bioassays</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Media releases on research findings</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>071A43C2-00C5-40D2-A73E-EC026C132A46</gtr:id><gtr:impact>University press releases on the novel Alzheimer drug hits we discovered, along with developments in synthetic chemistry of our sugars, and applications in nerve repair and cancer therapeutics

International press coverage, radio interviews (Radio City Liverpool), and TV news (BBC NW Tonight).</gtr:impact><gtr:outcomeId>664F9A23EAF</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Lecture to Garston Rotary Club</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>42FF2C14-E422-4E15-989E-0D008A11EFE2</gtr:id><gtr:impact>Lecture to Garston Rotary Club

Contributing the Public Understanding of Science</gtr:impact><gtr:outcomeId>E03C6115FF2</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RCUK/BBSRC event: Lifelong Health: Bioscience of Ageing (at Westminster)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FF281884-E181-4ACF-BC8E-186774D98867</gtr:id><gtr:impact>Poster highlighting discovery of new class of drugs for AD at the RCUK/BBSRC event: 2007 Lifelong Health: Bioscience of Ageing (at Westminster)

Dissemination of information on research success to MPs and policymakers</gtr:impact><gtr:outcomeId>4FDB8F2C434</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Supporting ARUK fund raising publicity with major London donor</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>617480B8-1CB7-4869-BC82-9845926BC013</gtr:id><gtr:impact>Supporters engaged directly with researcher undertaking research activity.

As above</gtr:impact><gtr:outcomeId>53889defdeaad5.02672164</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Hosting visit to Liverpool University by local ARUK funding supporters</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>38147378-AE29-4EA4-A798-9E916C7E6B66</gtr:id><gtr:impact>Contact was invaluable in informing supporters directly about research activities supported in Liverpool by their fund raising efforts

Funding supporters were able to gain insights into new potential treatments for AD, and how their funding is used for research.</gtr:impact><gtr:outcomeId>53889ecec48c68.47147256</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public lecture to Liverpool Soroptimists Club</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A359C12D-539A-4A41-A130-9861FAC0F01D</gtr:id><gtr:impact>Talk sparked many questions and discussion of AD and potential new drugs and diagnostics

Contribution to Public Understanding of Science</gtr:impact><gtr:outcomeId>5464a2a09d1b27.42175603</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Outreach to Business Community</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EEB824A3-8EF4-4E94-B9D8-19D34D7CD4CC</gtr:id><gtr:impact>Article in magazine Research Intelligence by UoL Business Gateway,(see website link &amp;quot;Sweet Smell of Success&amp;quot; http://www.liv.ac.uk/researchintelligence/issue30/alzheimers.html)

Dissemination of information to business community</gtr:impact><gtr:outcomeId>5ABD8E4DF77</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:url>http://www.liv.ac.uk/researchintelligence/issue30/alzheimers.html</gtr:url><gtr:year>2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>Further preclinical development of candidate compounds as inhibitors of BACE1 for treatment of AD</gtr:description><gtr:firstYearOfImpact>2010</gtr:firstYearOfImpact><gtr:id>33B93261-FBBB-4032-A27C-0A252C981B42</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>5464c1062c2b35.71495826</gtr:outcomeId><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Novel glycodendrimers with potent bioactivities, including inhibition of BACE1.</gtr:description><gtr:grantRef>BB/D525713/1</gtr:grantRef><gtr:id>35E29CDF-FE0D-4C16-BD8B-F53CCE8CCDBD</gtr:id><gtr:impact>Still in early stage of development</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>5388984aadc598.72096154</gtr:outcomeId><gtr:patentId>PCT/NZ2012/000035</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Novel saccharide dendrimers</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Patent submitted on novel saccharide inhibitors of beta-secretase as potential therapeutics for Alzheimers disease</gtr:description><gtr:grantRef>BB/D525713/1</gtr:grantRef><gtr:id>3271F555-9BB5-41BE-A55A-8E77652FF913</gtr:id><gtr:impact>Licenced to IntelliHep Ltd, and ongoing patent costs will be paid by IntelliHep.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>m-9570957235.592379766a2f1c</gtr:outcomeId><gtr:patentId>WO2007/138263</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Saccharide inhibitors of beta-secretase</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Platform technology for generating selectively chemivcally modified heparins for drug discovery and biotechnology applications</gtr:description><gtr:grantRef>BB/D525713/1</gtr:grantRef><gtr:id>610B5C1B-98BA-4E5E-B6BA-D46D70502F6B</gtr:id><gtr:impact>Licences to University of Liverpool spin out IntelliHep Ltd for exploitation.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>E9D4C264689</gtr:outcomeId><gtr:patentId>US2006240473</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Engineered heparins</gtr:title><gtr:yearProtectionGranted>2006</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Novel fully synthetic beta-secretase inhibitors with potential as disease-modifying treatment for AD</gtr:description><gtr:grantRef>BB/D525713/1</gtr:grantRef><gtr:id>9E264B7A-CCC8-4AC0-81B6-0B44D089EF29</gtr:id><gtr:impact>Further development being undertaken in collaboration with University of Liverpool, and spinout IntelliHep.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>sKGFToGQKWx</gtr:outcomeId><gtr:patentId>WO2012121617</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Synthetic beta-secretase inhibitors</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Novel class of beta-secretase inhibitors based on natural heparin glycans, with potential as first in class disease-modifying treatment for AD</gtr:description><gtr:grantRef>BB/D525713/1</gtr:grantRef><gtr:id>080F2B02-E089-48B9-865A-16501CC75618</gtr:id><gtr:impact>IP licensed to University of Liverpool spinout IntelliHep and currently in further development</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>XZcP2tEr4cu</gtr:outcomeId><gtr:patentId>WO2007138263</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Beta-secretase inhibitors for Alzheimers disease</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>Developed candidate compounds as inhibitors of BACE1 for treatment of AD</gtr:description><gtr:exploitationPathways>Further translational research</gtr:exploitationPathways><gtr:id>CDA51770-B371-4F90-B95E-ADEBD99B05E8</gtr:id><gtr:outcomeId>5464c0ce4f59f1.84855567</gtr:outcomeId><gtr:sectors><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Developed a brain tissue slice ex vivo culture assay which allows screening of the effects of exogenous compounds on brain tissue biochemistry. This is particularly useful for obtaining data on the activity of for example BACE1 inhibitors on Abeta levels, using transgenic mouse models.</gtr:description><gtr:id>8D81F1BA-C80C-4814-BA98-52FB2EE2D0DE</gtr:id><gtr:impact>Publication in preparation for submission.</gtr:impact><gtr:outcomeId>53889cf9180df8.14721437</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Novel brain slice assays for ex vivo screening in transgenic mouse models</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Development of technologies for and production of complex libraries of HS saccharides</gtr:description><gtr:id>D944E227-0EA2-4697-9E12-1B95CA55B401</gtr:id><gtr:impact>Novel discoveries of structure-activity relationships for complex HS saccharides of relevance to biological and disease processes</gtr:impact><gtr:outcomeId>E4D9497A220</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Heparan sulphate saccharide libraries</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Libraries of selectively chemically modified heparins for applications in heparin-based drug discovery.</gtr:description><gtr:id>E52DF23B-8370-43C2-83A6-360B820B0DAB</gtr:id><gtr:impact>Exploited for a number of publications and to develop drug leads for AD, malaria, ant-cancer therapeutics and spinal repair therapies.</gtr:impact><gtr:outcomeId>CF594137A64</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Engineered heparins</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>IntelliHep Ltd</gtr:companyName><gtr:description>Spin-out company from University of Liverpool aiming to exploit engineered heparins in drug discovery and biotechnology applications. Company has a number of collaborative projects with external partners, and is also developing an internal pipeline of projects. Company is pre-investment and established a lab in 2010 and seeking further grant and investment income.; http://www.intellihep.com/</gtr:description><gtr:id>A12EFB12-F69B-4D0B-8A25-379922AFA6BF</gtr:id><gtr:impact>Early stage development of hit compounds as beta-secretase inhibitors for treating the underlying cause of Alzheimers disease. Option to licence IP from Liverpool University on an anticancer metastatic drug. Employment of research staff and regular funded projects sub-contracted into University labs. Collaborating with China partners on commercial applications of heparin by-products.</gtr:impact><gtr:outcomeId>1D2B8E8802C</gtr:outcomeId><gtr:url>http://www.intellihep.com/</gtr:url><gtr:yearCompanyFormed>2006</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>03BC335C-3352-40F9-AF37-7A3F5D9B8ACD</gtr:id><gtr:title>Novel ex vivo transgenic mouse brain tissue assay for screening BACE1 inhibitors</gtr:title><gtr:parentPublicationTitle>Nature Methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/092804ddacbc4778ce8b19029aa8303d"><gtr:id>092804ddacbc4778ce8b19029aa8303d</gtr:id><gtr:otherNames>Guimond, SE</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>5388995506e937.40738742</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED8E3509-C7B3-4904-8930-9107715467A8</gtr:id><gtr:title>Engineered heparins: novel beta-secretase inhibitors as potential Alzheimer's disease therapeutics.</gtr:title><gtr:parentPublicationTitle>Neuro-degenerative diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c3b7fef8dafe1d37d73127af64c17a7"><gtr:id>5c3b7fef8dafe1d37d73127af64c17a7</gtr:id><gtr:otherNames>Patey SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1660-2854</gtr:issn><gtr:outcomeId>3C5A769EDC7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37017010-1E62-4270-A872-1C8FC5389590</gtr:id><gtr:title>Oligosaccharide agents for treating Neurodegeneration</gtr:title><gtr:parentPublicationTitle>Patent WO2007/138263</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c216653e3a5e46bcdd1beb97b36eb008"><gtr:id>c216653e3a5e46bcdd1beb97b36eb008</gtr:id><gtr:otherNames>Patey S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:outcomeId>7A60D09A1D1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A15862E-C4D5-478D-ABAC-D4AD66743295</gtr:id><gtr:title>Heparan sulphate glycodendrimers with potent bioactivities: tools for chemical biology and therapeutic development.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fb614b3ab31aae44505c52c29cd6243"><gtr:id>7fb614b3ab31aae44505c52c29cd6243</gtr:id><gtr:otherNames>Zubkova, O</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>53889af710c159.92263728</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B9C423A-FEF8-4ADC-819D-BB527786B180</gtr:id><gtr:title>Identification of Orally Available Synthetic Heparinoids with Potent BACE1 Inhibitory Properties</gtr:title><gtr:parentPublicationTitle>Nature Biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02ff6f916a640dd4c53546bda256c381"><gtr:id>02ff6f916a640dd4c53546bda256c381</gtr:id><gtr:otherNames>Turnbull, JE</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>53889a3be21c88.21151337</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A07C6B35-AD4B-48AF-980A-B875659A124D</gtr:id><gtr:title>Heparin derivatives as inhibitors of BACE-1, the Alzheimer's beta-secretase, with reduced activity against factor Xa and other proteases.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c3b7fef8dafe1d37d73127af64c17a7"><gtr:id>5c3b7fef8dafe1d37d73127af64c17a7</gtr:id><gtr:otherNames>Patey SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>4DC368FC6A7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BAF683D-733A-4F83-8A5C-46922D475E45</gtr:id><gtr:title>Engineered bio-active polysaccharides from heparin.</gtr:title><gtr:parentPublicationTitle>Macromolecular bioscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4f51e190a92a1cba9a8042b8d614d69"><gtr:id>b4f51e190a92a1cba9a8042b8d614d69</gtr:id><gtr:otherNames>Guimond SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1616-5187</gtr:issn><gtr:outcomeId>DFBAB38D607</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84293BB1-F1ED-4BF0-8527-D84C4F794EA3</gtr:id><gtr:title>Modular synthesis of heparan sulfate oligosaccharides for structure-activity relationship studies.</gtr:title><gtr:parentPublicationTitle>Journal of the American Chemical Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/244b86ec829ab877769ec997e4ed009b"><gtr:id>244b86ec829ab877769ec997e4ed009b</gtr:id><gtr:otherNames>Arungundram S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0002-7863</gtr:issn><gtr:outcomeId>A5C3724F86A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB2A2238-B29E-4030-ABD9-B33AEF19FADD</gtr:id><gtr:title>Synthesis of a targeted library of heparan sulfate hexa- to dodecasaccharides as inhibitors of ?-secretase: potential therapeutics for Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Chemistry (Weinheim an der Bergstrasse, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50dd39d48ac6d8d38b428a78a915072c"><gtr:id>50dd39d48ac6d8d38b428a78a915072c</gtr:id><gtr:otherNames>Schw?rer R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0947-6539</gtr:issn><gtr:outcomeId>538305a2274854.91159051</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/D525713/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>